BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

DakoCytomation A/S Launches Marketing Of ReSSQ EBV Assay


10/19/2005 5:10:26 PM

HUDDINGE, Sweden and GLOSTRUP, Denmark, Sept. 2 /PRNewswire/ -- LightUp Technologies AB and DakoCytomation A/S today announced the market introduction of ReSSQ(TM) EBV Assay, a nucleic acid test (NAT) for detection and quantification of Epstein-Barr virus. The assay provides a rapid and accurate means of monitoring viral load of EBV in clinical specimens. Currently, it is validated for use in conjunction with the LightCycler(R) and ABI PRISM(R) 7000 SDS real-time PCR instrument platforms.

Ulrica Sehlstedt, Ph.D., Chief Executive Officer, commented, "The ReSSQ EBV Assay represents the most recent addition to our developing portfolio of products for infectious disease diagnostics. It follows our strategy to provide clinical laboratories with robust and cost effective diagnostic kits. As one component in the prevention of disease and management of infections, we are proud of being able to provide the healthcare community with an efficient and easy to use tool to monitor viral load before, during and after treatment of patients with EBV."

In June, LightUp Technologies and DakoCytomation announced a European distribution agreement. Under the agreement, ReSSQ EBV Assay will be marketed and sold by DakoCytomation in Europe. Eventually, the assay will be made available throughout the world.

Geoff Gower, Director of Microbiology at DakoCytomation, said, "We are happy to make this product available to clinicians and clinical laboratories involved in the management of immunocompromised patients. EBV infection is, for example, a major risk factor for developing lymphoproliferative disease (PTLD), a life-threatening complication of organ transplantation."

To meet company representatives and learn more about the ReSSQ Assays and the LightUp(R) Probe diagnostic platform technology, stop by the LightUp Technologies and DakoCytomation Booth No. 10 at the ESCV EuroVirology 2004 meeting on September 5-8 in Madrid.

About LightUp Technologies AB

LightUp Technologies AB is a company developing and commercialising innovative technologies for the fast-growing molecular diagnostic segment of the in vitro diagnostics (IVD) industry. Our first product range, the ReSSQ Assays, enables simpler and more accurate identification and quantification of disease-generating organisms. The unique LightUp Probe at the heart of the method is designed to work with real-time PCR and can be used in many medical applications, including gene mapping and disease diagnostics. LightUp Technologies was founded in 1998 and is located in Huddinge, south of Stockholm, Sweden. For more information, visit our web site at http://www.lightup.se/

About DakoCytomation A/S

DakoCytomation A/S, headquartered in Copenhagen, Denmark, is a leading cancer diagnostics company with a focus on personalized medicine. DakoCytomation offers systems solutions for clinical laboratories and life science researchers, providing tests and instruments so that physicians can link diagnostic results to specific therapies and optimize patient care. The privately held company has significant R&D and manufacturing activities in Denmark, UK and USA, with operations in 20 countries, distributors in 50+ countries and more than 1,300 employees. http://www.dakocytomation.com/

http://hugin.info/134553/R/959328/137964.pdf For more information, contact: Ulrica Sehlstedt, Ph.D. Chief Executive Officer LightUp Technologies AB Direct line: +46 8 556 40 661 email: ulrica.sehlstedt@lightup.se Gitte Sjorslev Communications Manager DakoCytomation A/S Direct line: +45 44 85 93 31 Cellular phone: +45 40 63 95 93 email: gitte.sjorslev@dakocytomation.com

LightUp Technologies AB

CONTACT: Ulrica Sehlstedt, Ph.D. Chief Executive Officer, of LightUpTechnologies AB, +46-8-556-40-661, ulrica.sehlstedt@lightup.se; or GitteSjorslev, Communications Manager of DakoCytomation A/S, +45-44-85-93-31, orcellular, +45-40-63-95-93, gitte.sjorslev@dakocytomation.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES